About Nohla Therapeutics
Nohla Therapeutics is a company based in Seattle (United States) founded in 2015 by Colleen Delaney. It operates as a B2B. Nohla Therapeutics has raised $120.5 million across 4 funding rounds from investors including Fidelity Investments, ARE and Celgene. The company has 48 employees as of December 31, 2018. Nohla Therapeutics operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Seattle, United States
- Employees 48 as on 31 Dec, 2018
- Founders Colleen Delaney
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Nohla Therapeutics Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$120.5 M (USD)
in 4 rounds
-
Latest Funding Round
$11 M (USD), Series B
Jul 11, 2018
-
Investors
Fidelity Investments
& 9 more
-
Employee Count
48
as on Dec 31, 2018
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Nohla Therapeutics
Nohla Therapeutics has successfully raised a total of $120.5M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $11 million completed in July 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Nohla Therapeutics
Nohla Therapeutics has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, ARE and Celgene.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Seed and Early stage VC firm investing in Japan
|
Locked | Locked | Locked | |
|
Private equity & venture capital firm
|
Locked | Locked | Locked | |
|
Venture capital firm focused on life science companies
|
Locked | Locked | Locked |
Investor details for Nohla Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Nohla Therapeutics
Investment portfolio details for Nohla Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Nohla Therapeutics
Detailed financials for Nohla Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nohla Therapeutics Comparisons
Peer comparison for Nohla Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Nohla Therapeutics
Nohla Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of Nohla Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nohla Therapeutics
Complete news archive for Nohla Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nohla Therapeutics
Nohla Therapeutics was founded in 2015.
Nohla Therapeutics is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Nohla Therapeutics is a funded company, having raised a total of $120.5M across 4 funding rounds to date.
As of Dec 31, 2018, the latest employee count at Nohla Therapeutics is 48.
Nohla Therapeutics, founded in 2015 in Seattle, United States, focuses on providing healthcare solutions, advancing biotech innovations, therapeutics, and stem-cell treatments. Develops stem-cell transplant solutions using umbilical cord blood as an alternative to bone-marrow transplants. The company is dedicated to excellence, innovation, and customer satisfaction, ensuring sustainable practices and long-term success in its sectors.
Nohla Therapeutics's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Nohla Therapeutics has 10 investors. Key investors include Fidelity Investments, ARE, Celgene, Arch Venture Partners, and UT-EC Japan.